NCT06505486View on ClinicalTrials.gov

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

RecruitingOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Gemcitabine-Oxaliplatin Regimen

Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER